 DELRAY BEACH, Fla., April 15, 2021 GLOBE NEWSWIRE -- AzurRx BioPharma, Inc. NASDAQ: AZRX, AzurRx or the Company, a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal GI diseases, today issued a letter to its shareholders from James Sapirstein, President, Chief Executive Officer and Chairman, highlighting the companys corporate and clinical achievements during the first quarter of 2021 and recent weeks. 